Quick Answer: Tirzepatide is a synthetic dual GIP and GLP-1 receptor agonist. It is MHRA-approved as Mounjaro for type 2 diabetes and obesity in the UK. Phase 3 SURMOUNT trials demonstrated up to 22.5% body weight loss. It is mechanistically distinct from — and clinically superior to — single GLP-1 agonists like semaglutide in head-to-head data. Research-grade tirzepatide peptide is available for laboratory use from UK suppliers.
What Is Tirzepatide?
Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. It is the world’s first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — meaning it activates two distinct hormone receptors simultaneously rather than the single GLP-1 receptor targeted by earlier weight-loss drugs like semaglutide and liraglutide.
In the UK, tirzepatide is licensed by the MHRA as Mounjaro for the treatment of type 2 diabetes mellitus and, subsequently, for weight management in adults with obesity or overweight with weight-related comorbidities. The FDA approved Mounjaro in the United States in May 2022 for type 2 diabetes, and Zepbound for obesity in November 2023.
Tirzepatide is not a traditional peptide in the same category as BPC-157 or TB-500 (which are research-only compounds with no approved clinical use). It has undergone one of the largest and most rigorously designed clinical development programmes in metabolic disease history, with multiple Phase 3 trials enrolling tens of thousands of participants. The research and clinical evidence base for tirzepatide is therefore substantially more developed than for any other peptide covered in this guide series.
How Does Tirzepatide Work? The Dual GIP/GLP-1 Mechanism
The defining feature of tirzepatide — and the explanation for its superior metabolic effects compared to semaglutide — is its simultaneous activation of both GIP and GLP-1 receptors. Understanding why this dual mechanism matters requires understanding what each receptor does individually and what happens when they are activated together.
GLP-1 Receptor Activation
GLP-1 (glucagon-like peptide-1) is an incretin hormone produced by L-cells in the intestinal mucosa in response to food ingestion. Its physiological effects include stimulating glucose-dependent insulin secretion from pancreatic beta cells, inhibiting glucagon secretion from alpha cells (which reduces hepatic glucose output), slowing gastric emptying (which prolongs satiety and blunts postprandial glucose spikes), and acting on the hypothalamus to reduce appetite and food intake.
GLP-1 receptor agonists like semaglutide exploit these effects pharmacologically — at drug doses, they produce sustained GLP-1 receptor activation with clinically meaningful reductions in HbA1c and body weight. Tirzepatide activates the same GLP-1 receptor, but as part of a combined mechanism rather than in isolation. For more detail: How Does Tirzepatide Work?
GIP Receptor Activation: The Differentiator
GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, produced by K-cells in the duodenum and proximal jejunum. Like GLP-1, it stimulates glucose-dependent insulin secretion. However, GIP also has important additional metabolic effects that GLP-1 does not — particularly on adipose tissue. GIP receptors are highly expressed in fat tissue, and GIP appears to play a role in regulating fat storage and fatty acid metabolism.
What makes GIP’s contribution to tirzepatide’s mechanism particularly interesting is that GIP was historically thought to be a “bad” incretin in people with obesity and type 2 diabetes — its insulinotropic effects were known to be blunted. Lilly’s insight was that GIP receptor agonism (rather than just endogenous GIP signalling) might overcome this resistance and add metabolic benefits complementary to GLP-1 agonism.
Why Dual Agonism Produces Superior Results
The synergy of GIP and GLP-1 receptor co-activation explains why tirzepatide consistently outperforms single GLP-1 agonists in clinical endpoints. In the SURPASS-2 head-to-head trial vs semaglutide 1mg, tirzepatide at 10mg and 15mg produced statistically significantly greater HbA1c reductions and body weight loss. The GIP component appears to add appetite-suppressing effects via a central nervous system mechanism distinct from GLP-1’s hypothalamic pathway, as well as direct metabolic effects on adipose and muscle tissue.
Additional relevant mechanisms: tirzepatide slows gastric emptying (contributing to prolonged satiety), reduces food reward signalling in the brain, and may improve insulin sensitivity beyond the effects attributable to weight loss alone. For weight loss mechanism detail: How does Tirzepatide make you lose weight? and How does Tirzepatide cause weight loss?
Tirzepatide Clinical Trial Data: SURPASS and SURMOUNT
Tirzepatide’s evidence base is among the strongest in metabolic medicine. The two major Phase 3 programme families — SURPASS (type 2 diabetes) and SURMOUNT (obesity/overweight) — collectively enrolled tens of thousands of participants and established tirzepatide’s efficacy across multiple populations and comparators.
SURMOUNT-1: Obesity Weight Loss Data
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022; PMID: 35658024) is the landmark obesity trial for tirzepatide. 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity) were randomised to tirzepatide 5mg, 10mg, or 15mg once weekly, or placebo, for 72 weeks. Results:
| Dose | Mean % Body Weight Loss | % Achieving ≥20% Weight Loss |
|---|---|---|
| Tirzepatide 5mg | −15.0% | 30.5% |
| Tirzepatide 10mg | −19.5% | 49.5% |
| Tirzepatide 15mg | −20.9% (up to 22.5% in some analyses) | 56.8% |
| Placebo | −2.4% | 1.6% |
These results represented the largest weight loss ever demonstrated by a pharmaceutical agent in a Phase 3 trial at that time, surpassing semaglutide’s 14.9% in the STEP-1 trial. For more on expected results: What results can I expect from Tirzepatide? and How much weight can you lose on Tirzepatide?
SURPASS Programme: Type 2 Diabetes Data
The SURPASS programme (SURPASS-1 through SURPASS-5) established tirzepatide’s efficacy in type 2 diabetes, including the critical head-to-head SURPASS-2 trial vs semaglutide 1mg. At 40 weeks, tirzepatide 10mg and 15mg produced HbA1c reductions of −2.24% and −2.30% respectively, vs −1.86% for semaglutide 1mg. Weight loss was similarly superior: −7.8kg and −9.3kg vs −5.3kg. These findings formed the basis for MHRA approval as Mounjaro.
Tirzepatide vs Semaglutide: What the Data Actually Shows
| Feature | Tirzepatide (Mounjaro) | Semaglutide (Wegovy/Ozempic) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | Single GLP-1 receptor agonist |
| Max obesity dose | 15mg once weekly | 2.4mg once weekly (Wegovy) |
| Weight loss (obesity trial) | 22.5% (SURMOUNT-1, 15mg) | 14.9% (STEP-1, 2.4mg) |
| HbA1c reduction (T2D) | Up to −2.30% (SURPASS-2) | −1.86% (SURPASS-2 comparator) |
| MHRA-approved indications | T2D + obesity (Mounjaro) | T2D (Ozempic) + obesity (Wegovy) |
| GI side effects | Similar — nausea, vomiting, diarrhoea | Similar — nausea, vomiting, diarrhoea |
For a detailed comparison: Is Tirzepatide better than Semaglutide?
Tirzepatide vs Retatrutide: Triple vs Dual Agonism
While tirzepatide is a dual GIP/GLP-1 agonist, retatrutide (LY3437943) adds a third target — the glucagon (GCG) receptor. This triple agonism is the basis for retatrutide’s Phase 2 trial result of 24.2% body weight loss (Jastreboff et al., NEJM, 2023; PMID: 37369579), which numerically exceeds tirzepatide’s 22.5% in SURMOUNT-1, though the trials are not directly comparable.
The key distinction in 2026: tirzepatide is MHRA-approved and has completed Phase 3 trials. Retatrutide remains investigational, having completed only Phase 2 with Phase 3 ongoing. For UK researchers interested in the comparative pharmacology: Retatrutide vs Tirzepatide: Which Peptide Is More Effective for Fat Loss? and the full Retatrutide UK: Complete Research Guide (2026).
Tirzepatide Safety Profile and Side Effects
The safety profile of tirzepatide is well-characterised across a large clinical trial population. The most common adverse events are gastrointestinal:
- Nausea: Most common GI event, reported in approximately 15–40% of participants depending on dose; typically highest during dose escalation and diminishing over time
- Vomiting: ~10–20% at therapeutic doses; peaks during dose escalation
- Diarrhoea: ~10–20%; often transient
- Constipation: Less common; more prevalent at higher doses
- Decreased appetite: Intended pharmacological effect; leads to reduced caloric intake
Serious adverse events of note:
- Pancreatitis: Rare; class effect across GLP-1 receptor agonists. Patients with history of pancreatitis should exercise caution
- Thyroid C-cell tumours: Tirzepatide carries a boxed warning based on rodent studies showing thyroid C-cell tumours at supratherapeutic doses. The human relevance has not been established and is considered likely species-specific, but tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
- Hypoglycaemia: Low risk when used alone (glucose-dependent mechanism); risk increases when used with insulin or sulphonylureas
For detailed adverse event profiles: Does Tirzepatide cause heart problems? and Does Tirzepatide Cause Joint Pain?
Tirzepatide Legal Status in the UK (2026)
The regulatory status of tirzepatide in the UK requires careful distinction between two distinct categories:
Mounjaro (Licensed Medicine)
Tirzepatide as Mounjaro is a prescription-only medicine (POM) licensed by the MHRA for type 2 diabetes mellitus. It is also licensed for weight management in adults with obesity or overweight with weight-related comorbidities. It is legally available in the UK through the NHS or private prescriptions from registered prescribers. It cannot be lawfully supplied without a valid prescription. For the current regulatory position: Is Tirzepatide legal in the UK?
Research-Grade Tirzepatide
Tirzepatide in research-grade peptide form, supplied for laboratory use with clear “for research use only / not for human consumption” labelling, occupies a different regulatory category. It is not the same product as the licensed medicine. UK suppliers of research peptides may supply tirzepatide for legitimate laboratory research purposes. Purchasers should ensure they are buying from a supplier that provides independent HPLC purity verification and batch-specific Certificates of Analysis, and that the intended use is genuinely for research.
For the full picture on UK peptide law: Are peptides legal in the UK?
Tirzepatide Reconstitution and Storage for Research Use
Storage
- Lyophilised (powder) form: Store at -20°C for long-term stability. Short-term storage at 2–8°C acceptable for up to 3 months. Protect from light and moisture.
- Reconstituted solution: Store at 2–8°C. Use within 28 days. Do not freeze. Protect from light. Do not use if solution is cloudy or contains particulates.
Reconstitution
- Reconstitute with bacteriostatic water (0.9% benzyl alcohol in sterile water) for laboratory applications
- Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake
- Swirl gently to dissolve — do not shake or vortex
- A correctly reconstituted solution should be clear and colourless
Sourcing Research-Grade Tirzepatide in the UK
For researchers requiring tirzepatide peptide for laboratory investigation, quality verification is critical. Key standards:
- Purity ≥98% by HPLC, with a batch-specific COA from an independent third-party laboratory
- Molecular weight confirmation by mass spectrometry (tirzepatide MW: approximately 4,813 Da)
- Endotoxin testing for in-vivo research applications
- UK-dispatched stock to eliminate cold-chain risk during international transit
Peptides Lab UK supplies independently HPLC-tested, batch-COA-verified tirzepatide dispatched from UK stock. All products are clearly labelled for research use only, in full compliance with UK regulatory requirements.
View the verified Tirzepatide product page at Peptides Lab UK →
Tirzepatide Supporting Research: The Complete Cluster
- What does Tirzepatide do?
- How Does Tirzepatide Work?
- How does Tirzepatide make you lose weight?
- How does Tirzepatide cause weight loss?
- Can Tirzepatide help with weight loss?
- How much weight can you lose on Tirzepatide?
- What results can I expect from Tirzepatide?
- Tirzepatide before and after
- Is Tirzepatide better than Semaglutide?
- Does Tirzepatide increase insulin?
- Does Tirzepatide cause heart problems?
- Does Tirzepatide Cause Joint Pain?
- Is Tirzepatide FDA Approved?
- Is Tirzepatide legal in the UK?
- Can you buy Tirzepatide online?
- Retatrutide vs Tirzepatide: Which Peptide Is More Effective for Fat Loss?
Frequently Asked Questions: Tirzepatide UK Research
What is Tirzepatide?
Tirzepatide is a synthetic dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is MHRA-approved as Mounjaro for type 2 diabetes and weight management, and represents the most clinically validated weight-loss peptide available.
How does Tirzepatide cause weight loss?
By activating both GIP and GLP-1 receptors, tirzepatide reduces appetite (hypothalamic effects), slows gastric emptying (prolonging satiety), reduces food reward signalling, stimulates glucose-dependent insulin secretion, and exerts direct metabolic effects on adipose tissue. The combination of these mechanisms produces greater weight loss than either mechanism alone.
How much weight can you lose on Tirzepatide?
In SURMOUNT-1, participants on 15mg tirzepatide lost an average of 20.9–22.5% of body weight over 72 weeks. Approximately 56.8% of participants achieved ≥20% weight loss. This is the largest weight loss demonstrated by any pharmaceutical agent in a Phase 3 obesity trial as of 2026.
Is Tirzepatide better than Semaglutide?
In direct head-to-head data (SURPASS-2), tirzepatide 10mg and 15mg produced greater HbA1c reductions and weight loss than semaglutide 1mg. For obesity, tirzepatide’s 22.5% weight loss in SURMOUNT-1 exceeds semaglutide’s 14.9% in STEP-1. The dual GIP/GLP-1 mechanism is the proposed driver of the difference.
Is Tirzepatide legal to buy in the UK for research?
Research-grade tirzepatide peptide is legal to purchase for legitimate laboratory research from a compliant UK supplier. It must be clearly labelled for research use only. Mounjaro (the licensed medicine) requires a valid prescription.
